Misleading Health Ads: The Watchdog Barks. Who Bites?

The promise comes with a deadline. Lose six kilograms in 60 days. Make your skin look seven years younger. Get rid of thigh fat in 12 weeks.

The evidence appears to have a more flexible schedule.

In its latest review of nutraceutical advertising, the Advertising Standards Council of India found repeated instances of health promises running ahead of adequate substantiation. Some advertisements suggested supplements could cleanse smokers’ lungs. Others ventured into claims involving asthma, chronic obstructive pulmonary disease and PCOD.

When challenged, 29 advertisers modified or withdrew their advertisements without contest. Another 31 cases were found in violation of ASCI’s code. One remained under review. None of the advertisers who contested the complaints provided adequate evidence to substantiate their promises, the report says.

That produces an encouraging administrative outcome: an advertisement changes or disappears.

For somebody who has already paid for the product, however, the problem may be considerably less settled.

Was the buyer told that the claim had been challenged? Did a correction reach the people who saw the original advertisement? Was a refund offered? Did any statutory authority impose a penalty?

ASCI’s report does not answer those questions. That is the accountability gap its findings bring into focus.

The advertisement goes. What happens to the purchase?

ASCI examined 61 nutraceutical advertisements between July and September 2026 for its report, A Pill for Thought. All 60 completed cases required some modification.

This was a targeted investigation into advertisements promoting health claims. It was not a representative survey of the entire industry, and its findings cannot establish that every supplement advertisement in India is misleading.

The distinction between the outcomes also matters. Twenty-nine advertisers changed or withdrew their ads without contest; 31 cases resulted in findings of code violations. Those are different routes to resolving a complaint.

Neither outcome, by itself, tells us what happened to customers.

Stopping an unsupported claim can prevent further purchases based on that promise. It cannot automatically correct the understanding of people who encountered it earlier. A consumer may continue using the product, recommend it to somebody else or remain convinced that the advertised result is achievable.

These are possible consequences requiring investigation. The report does not document individual purchases, financial losses or medical harm.

But a consumer-protection system needs to examine what happened before the advertisement disappeared as carefully as it checks whether the advertisement is still running.

How an ingredient study becomes a product promise

One recurring practice identified by ASCI was the use of research on individual ingredients to support claims about finished products.

The distinction is fundamental. Evidence that an ingredient produced a benefit under particular conditions does not automatically establish that a marketed capsule, gummy or spray will reproduce it. The formulation, dose, study population and outcome being measured all matter.

A claim about a finished product needs evidence relevant to the product as sold and the result being promised.

ASCI also identified comparisons whose benchmarks were unclear. “Faster” requires an answer to “faster than what?” A numerical promise requires evidence supporting that number.

Scientific language can make an advertisement sound reassuring. The consumer still needs to know whether the research supports the specific purchase being encouraged.

When wellness starts promising treatment

The stakes rise when advertising moves from general wellbeing into claims about medical conditions.

ASCI described advertisements implying that supplements could reverse damage from smoking or pollution, alongside claims involving blood sugar, respiratory illness and hormonal conditions. Before-and-after images made complicated health outcomes appear rapid and predictable.

Such representations could influence decisions about seeking appropriate medical care. That is a risk identified by the report, rather than evidence that particular patients abandoned treatment.

India already has rules addressing the boundary. FSSAI’s advertising and claims regulations generally prohibit food claims concerning the prevention, alleviation, treatment or cure of diseases unless specifically permitted under applicable regulations. They also set evidence requirements for health benefits attributed directly to products.

The relevant question is, therefore, how consistently those obligations are enforced before and after consumers encounter the claims.

ASCI can flag the claim. Statutory authorities have enforcement powers

The “watchdog without teeth” criticism needs to distinguish between institutions.

ASCI operates a self-regulatory system for advertising. Its code decisions are separate from statutory enforcement by bodies such as the Central Consumer Protection Authority and food-safety authorities.

The CCPA can order the discontinuation or modification of misleading advertisements. Under the Consumer Protection Act, penalties on manufacturers or endorsers can extend to ₹10 lakh, rising to ₹50 lakh for subsequent contraventions. These are legal ceilings, not automatic penalties for every ASCI finding.

The authority also has powers concerning recalls, refunds and the discontinuation of unfair practices, subject to the applicable legal process.

The enforcement system therefore has powers beyond requesting a change of wording. What the nutraceutical report does not disclose is whether these particular cases generated referrals, investigations, penalties or consumer remedies.

Without that follow-through, readers can see the offending promises and the complaint outcomes, but cannot assess the full consequences for advertisers.

Is withdrawal becoming the measure of success?

An advertiser’s decision to withdraw a claim is useful. It should prompt further questions.

How long did the advertisement run? How many people saw it? Was the same promise repeated on product pages, packaging, influencer videos or marketplace listings? Did the correction cover all those places?

Repeat behaviour matters, too. An advertiser correcting its first challenged campaign presents a different enforcement problem from one repeatedly returning with similar claims.

The report does not establish that withdrawal is being used deliberately to escape accountability. Nor does it provide enough information to conclude that penalties are absent or ineffective across the industry.

It does reveal why counting modified advertisements is an incomplete measure of consumer protection.

A stronger public accounting would follow each case from the original claim through the evidence supplied, the time taken to intervene, the final correction and any subsequent statutory action. Where remedies are warranted, it should explain how buyers can obtain them.

The consumer who bought a supplement on Monday may never see the finding published on Friday.

The advertisement’s disappearance should not make that consumer disappear from the story.